Morgan Stanley Oncocyte Corp Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.2 - $0.35 $550,879 - $964,039	2,754,399 Added 7539.28%	2,790,933 $641,000
Q1 2023 May 15, 2023	SELL	$0.2 - $0.49 $1,502 - $3,679	-7,510 Reduced 17.05%	36,534 $12,000
Q4 2022 Feb 14, 2023	SELL	$0.25 - $0.69 $16,324 - $45,056	-65,299 Reduced 59.72%	44,044 $14,000
Q3 2022 Nov 14, 2022	SELL	$0.76 - $0.99 $29,715 - $38,708	-39,099 Reduced 26.34%	109,343 $80,000
Q2 2022 Oct 27, 2022	SELL	$0.86 - $1.53 $41,041 - $73,016	-47,723 Reduced 24.33%	148,442 $134,000

Q2 2022 Aug 15, 2022	SELL	$0.86 - $1.53 $41,041 - $73,016	-47,723 Reduced 24.33%	148,442 $134,000
Q1 2022 Oct 27, 2022	BUY	$1.15 - $2.25 $54,881 - $107,376	47,723 Added 32.15%	196,165 $292,000
Q1 2022 May 13, 2022	SELL	$1.15 - $2.25 $57,504 - $112,509	-50,004 Reduced 20.31%	196,165 $292,000
Q4 2021 Feb 14, 2022	BUY	$2.04 - $3.59 $330,339 - $581,332	161,931 Added 192.23%	246,169 $534,000
Q3 2021 Nov 15, 2021	BUY	$3.53 - $5.89 $297,360 - $496,161	84,238 New	84,238 $300,000

1.16M

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $350M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.